Is this email not displaying correctly?
View it in your browser.
Newswise - News for Journalists

Newswise Special Wire
Tuesday, September 29, 2015

Public edition | newswise.com

Newswise Cancer Research Wire for 29-Sep-2015
FacebookTwitterLinkedInStumbleupon

Cancer Research Wire

Cancer research news for the public and news media. More stories can be found at the Newswise Cancer News Source.

Breast Cancer Patients Whose Tumors Score Low on Multigene Test Can Safely Avoid Chemotherapy

A major study published in the New England Journal of Medicine is providing the best evidence to date that a 21-gene test done on the tumor can identify breast cancer patients who can safely avoid chemotherapy.

(Embargo expired on 28-Sep-2015 at 01:00 ET)

New England Journal of Medicine

– Loyola University Health System

Scientists Use Microchip Approach to Visualize Breast Cancer Proteins

Virginia Tech Carilion Research Institute scientists present a new molecular toolkit to investigate protein assemblies natively formed in the context of human disease. BRCA1 gene regulatory complexes from cancer cells were visualized for the first time.

 • Image(s) embedded • 

Scientific Reports, Sept-2015

– Virginia Tech

Immunotherapy Superior to Chemotherapy for Lung Cancer in International Trial

An international team of cancer researchers that included UT Southwestern Medical Center physicians announced “game-changing results” using the immunotherapy drug nivolumab to treat certain lung cancers that failed to respond to first-line therapies.

 • Image(s) embedded • 

New England Journal of Medicine

– UT Southwestern Medical Center

New Drug Improves Outcome in Treatment Resistant Kidney Cancer

A new drug for renal cell carcinoma slowed the growth of advanced kidney cancer in patients who became resistant to the first-line therapies that had previously kept it in check, according to results from a clinical trial led by Dana-Farber Cancer Institute.

 • Image(s) embedded • 

September 25, 2015DOI: 10.1056/NEJMoa1510016

– Dana-Farber Cancer Institute

Terrible News, Great Outcomes

A father and daughter each got a fighting chance against lung cancer, thanks to early detection and Rush's top-rated lung surgery program.

Expert(s) available

– Rush University Medical Center

Everolimus Improves Progression-Free Survival for Patients with Advanced, Nonfuctional Neuroendocrine Tumors of the Lung, Gastrointestinal Tract

In an international Phase III randomized study, everolimus, an inhibitor of the mammalian target of rapamycin (mTOR), has shown to dramatically improve progression-free survival for patients with advanced, nonfunctional neuroendocrine tumors (NET) of the lung and gastrointestinal tract.

 • Image(s) embedded •  (Embargo expired on 26-Sep-2015 at 18:05 ET)

– University of Texas M. D. Anderson Cancer Center

Plum Good Health Benefits

Researchers from Texas A&M University and the University of North Carolina have shown a diet containing dried plums can positively affect microbiota, also referred to as gut bacteria, throughout the colon, helping reduce the risk of colon cancer.

– Texas A&M AgriLife

Breakthrough Study Demonstrates Survival Advantage with Immune Checkpoint Inhibitor for Advanced Kidney Cancer Patients

For the first time, an immune checkpoint inhibitor has been proven to increase survival among patients with advanced renal cell carcinoma (RCC), a patient population for whom treatment options are currently limited.

 • Image(s) embedded •  (Embargo expired on 25-Sep-2015 at 18:05 ET)

New England Journal of Medicine

– University of Texas M. D. Anderson Cancer Center

New Methodology Tracks Changes in DNA Methylation in Real Time at Single-Cell Resolution

Whitehead Institute researchers have developed a tool that allows scientists to monitor changes in DNA methylation over time in individual cells. Certain diseases, including cancer, cause changes in DNA methylation patterns, and the ability to document these alterations could aid in the development of novel therapies.

(Embargo expired on 24-Sep-2015 at 12:00 ET)

Cell, Sept 24-2015; HD 045022

– Whitehead Institute for Biomedical Research

‘Remote Control’ of Immune Cells Opens Door to Safer, More Precise Cancer Therapies

UCSF researchers have engineered a molecular “on switch” that allows tight control over the actions of T cells, immune system cells that have shown great potential as therapies for cancer.

(Embargo expired on 24-Sep-2015 at 14:00 ET)

– University of California, San Francisco (UCSF)

MD Anderson Study Identifies Leukemia Tumor Suppressor

A protein-coding gene called hnRNP K has been identified as a tumor suppressor for acute myeloid leukemia (AML), a finding that could be important for investigating how best to target treatment of a blood cancer striking mostly older individuals.

(Embargo expired on 24-Sep-2015 at 12:00 ET)

Cancer Cell

– University of Texas M. D. Anderson Cancer Center

Arteries Better Than Veins for Liquid Biopsy

Arteries contain higher numbers of circulating tumor cells than veins in uveal melanoma patients, raising a concern for standard technique for detection of tumor cells in the blood.

EBioMedicine

– Thomas Jefferson University

Childhood Brain Tumors Affect Working Memory of Adult Survivors

Adult survivors of childhood brain tumors have lower working memory performance compared to healthy adults, according to researchers at Georgia State University and Emory University.

 • Image(s) embedded • 

Journal of the International Neuropsychological Society, August 2015

– Georgia State University

Would People be Happier -- and Healthier-- if They Thought Broccoli Tasted Like Chocolate?

A new science called Neurogastronomy brings chefs and neuroscientists together to improve quality of life for patients with taste & smell deficits. The inaugural International Society of Neurogastronomy symposium is November 7, 2015, featuring internationally-renowned chefs, scientists, and food technologists.

 • Video embedded • 

– University of Kentucky

Stem Cell Agency Invests Almost $20 Million in Clinical Trial for Deadly Brain Cancer

Glioblastoma is the most common and the most aggressive form of brain tumor, so funding an equally aggressive approach to treating it was a no-brainer for CIRM, California’s stem cell agency.

– California Institute for Regenerative Medicine (CIRM)

New Cancer Genes Identified, Opening Door to Targeted Treatments

Researchers have identified two new cancer-causing gene mutations – mutations that may be particularly susceptible to cancer-fighting drugs already approved by the federal Food and Drug Administration. One of the gene mutations also may play a key role in early menopause.

 • Image(s) embedded • 

Nature Communications

– University of Virginia Health System

In Terminally Ill Patients, Some Types of Delirium Are a Sign of 'Imminent Death'

In cancer patients nearing the end of life, certain subtypes of delirium—specifically, hypoactive and "mixed" delirium—are a strong indicator that death will come soon, reports a study in Psychosomatic Medicine: Journal of Biobehavioral Medicine, the official journal of the American Psychosomatic Society. The journal is published by Wolters Kluwer.

Psychosomatic Medicine

– Wolters Kluwer Health: Lippincott Williams and Wilkins

Molecular ‘Feedback Loop’ May Explain Tamoxifen Resistance in Patients with Breast Cancer

For reasons unknown, many patients with breast cancer treated with the estrogen receptor-blocking drug tamoxifen eventually become resistant to the treatment despite the fact that their cancer cells still have the estrogen receptor proteins that the drug normally targets. Now, Johns Hopkins Kimmel Cancer Center scientists and their colleagues have traced out an intricate molecular pathway in those cells they say may explain, at least in part, how tamoxifen resistance develops.

Cancer Discovery; SAC110050; W81XWH-04-1-0595; P30 CA006973; KG101506; OTKA K108655; SAC110025; R01HG006282

– Johns Hopkins Medicine

New Study Questions Clinical Trial Data for Kidney Cancer Drugs

A new study has shown that for certain cancer drugs, participants in clinical trials are often not representative of the patients that ultimately take the drugs, raising questions about the direct applicability of trial data.

Journal of Oncology Practice

– University of North Carolina Health Care System

New York State Approves Columbia University’s 467-Gene Cancer Panel

The Laboratory of Personalized Genomic Medicine at Columbia University Medical Center (CUMC) has been granted full approval by the New York State Department of Health for the Columbia Combined Cancer Panel, (CCCP).

– Columbia University Medical Center

Oxygen Treatment Boosts the Success of Umbilical Cord Blood Transplants

Clinical trial improves outcomes with safer, more effective therapy

 • Image(s) embedded • 

Robert K. Dempski Cord Blood Research Fund and SWOG/Hope Foundation

– University of Kansas Cancer Center

Announcements

Henry Ford Launches Detroit Campus Expansion with $110 Million Cancer Center

Henry Ford Health System plans to build a $110 million cancer center as part of a $500 million expansion and neighborhood improvement initiative on 300 acres in Detroit, marking another key development in the city’s revitalization and growth.

 • Image(s) embedded • 

– Henry Ford Health System

UAB School of Nursing Awarded Prestigious Komen Traineeship

Three-year grant will provide graduate scholars with stipends and other financial and educational support to pursue training in disparities research.

 • Image(s) embedded •  (Embargo expired on 25-Sep-2015 at 09:00 ET)

– University of Alabama at Birmingham

Helping Breast Cancer Patients with a Challenging Decision

Rutgers Cancer Institute of New Jersey investigators have been awarded a $404,089 grant from the National Cancer Institute to explore the decision making process women with non-hereditary breast cancer undergo when considering the removal of a healthy breast. The aim is to develop a web-based tool to aid them in this process.

 • Image(s) embedded • 

R21CA187643

– Rutgers Cancer Institute of New Jersey

Rutgers Cancer Institute of New Jersey Enhances Lung Cancer Focus with Arrival of Internationally-Recognized Surgeon

Aiming to enhance its focus on lung and other cancers of the chest, Rutgers Cancer Institute of New Jersey is welcoming Todd Demmy, MD, FACS, FCCP, as its new Chief of Thoracic Oncology and Associate Chief of the Division of Surgical Oncology. Dr. Demmy, who is leading Rutgers Cancer Institute’s Thoracic Oncology Program, is an international leader in minimally-invasive thoracic surgery and one of the pioneers of video-assisted thoracoscopic surgery (VATS).

 • Image(s) embedded • 

– Rutgers Cancer Institute of New Jersey

Higher Education Events

State’s Largest Cancer Research Fundraiser Slated for October 9 in Las Cruces

Cowboys for Cancer Research and the University of New Mexico Comprehensive Cancer Center will continue their 33-year tradition with this year’s annual fundraiser.

– University of New Mexico Comprehensive Cancer Center

Tips

CUSTOMIZE YOUR FAVORITES WITH "MY READING LIST"

MY CHANNELS
SAVED ARTICLES
MY SOURCES
MY EXPERTS *COMING SOON*

MORE CHANNELS:
JOURNAL NEWS
TRENDS AND TOP STORIES
LOCAL NEWS
MEDICAL and SCIENTIFIC MEETINGS

subscribe/unsubscribe :: edit my preferences
© 2015 Newswise, Inc. All Rights Reserved. | 215 E. 5th St. SW, Charlottesville VA 22903 | 434-296-9417 | Contact Us